Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group reported an anticipated revenue growth of 12-14% for the first half of fiscal year 2025, with expected revenues of $210-$215 million. This growth is attributed to strong performance in the Women’s Health segment and improved margins in Dermatology. The underlying EBITDA is projected to grow by 275-300% compared to the previous year. For the second half of FY25, the company aims to continue this growth trajectory despite anticipated seasonal cost impacts and increased promotional expenses. The cash and marketable securities stood at $124.9 million as of December 2024. These financial results underscore Mayne Pharma’s strategic execution and robust market positioning.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide patients with safer and more accessible medicines. The company also offers contract development and manufacturing services globally, leveraging a 40-year track record of innovation in developing new oral drug delivery systems.
YTD Price Performance: 1.56%
Average Trading Volume: 2,591
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $238.4M
Learn more about MYX stock on TipRanks’ Stock Analysis page.
